Purpurin

Purpurin

SCHEMBL2432647

O=C1c2ccccc2C(=O)c2c(O)c(O)cc(O)c21.O=C1c2ccccc2C(=O)c2c1ccc(O)c2O

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.80
KMT2A Q03164 7/20 0.80
MAPT P10636 7/20 0.80
MCL1 Q07820 6/20 0.80
MAOA P21397 4/20 0.80
ALDH1A1 P00352 4/20 0.80
MAPK1 P28482 4/20 0.80
HPGD P15428 4/20 0.80
TDP1 Q9NUW8 4/20 0.80
BCL2 P10415 4/20 0.80
KDM4E B2RXH2 3/20 0.80
CYP3A4 P08684 3/20 0.80
ALOX15 P16050 3/20 0.80
RECQL P46063 3/20 0.80
HSD17B10 Q99714 3/20 0.80
ALOX12 P18054 2/20 0.80
DAPK1 P53355 2/20 0.80
CYP1B1 Q16678 2/20 0.80
TTR P02766 2/20 0.80
BRCA1 P38398 2/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinalizarin SCHEMBL5709519 0.95 MAPT (0.77) MEN1KMT2AMAPTMCL1MAOA
Purpurin SCHEMBL4970376 0.91 MEN1 (0.96) MEN1KMT2AMAPTMCL1MAOA
Athraquinones A SCHEMBL4972786 0.89 MAPT (1.00) MEN1KMT2AMAPTMCL1MAOA
Athraquinones A SCHEMBL21114402 0.89 MAPT (1.00) MEN1KMT2AMAPTMCL1MAOA
Athraquinones A SCHEMBL29373337 0.89 MAPT (1.00) MEN1KMT2AMAPTMCL1MAOA
Athraquinones A SCHEMBL18614 0.89 MAPT (1.00) MEN1KMT2AMAPTMCL1MAOA
Purpurin SCHEMBL29429206 0.89 MEN1 (1.00) MEN1KMT2AMAPTMCL1MAOA
Purpurin SCHEMBL33871 0.89 MEN1 (1.00) MEN1KMT2AMAPTMCL1MAOA
Purpurin SCHEMBL29539242 0.89 MEN1 (1.00) MEN1KMT2AMAPTMCL1MAOA
Athraquinones A SCHEMBL7839563 0.88 MAPT (0.96) MEN1KMT2AMAPTMCL1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107205980-B Tissue and cell stain preparations with novel molecules obtained from corn poppy M·布达克 2020-04-07 CN claimed
US-20170315031-A1 TISSUE AND CELL STAIN FORMULA WITH A NOVEL MOLECULE OBTAINED FROM PAPAVER RHOEAS BUDAK MEHMET (TR) 2017-11-02 US claimed
EP-3209292-A1 TISSUE AND CELL STAIN FORMULA WITH A NOVEL MOLECULE OBTAINED FROM PAPAVER RHOEAS Budak, Mehmet (TR) 2017-08-30 EP claimed
EP-1366196-A4 METHODS AND COMPOSITIONS OF AMPLIFYING RNA BAYLOR COLLEGE MEDICINE (US) 2004-07-07 EP claimed
EP-1366196-A2 METHODS AND COMPOSITIONS OF AMPLIFYING RNA BAYLOR COLLEGE OF MEDICINE (US) 2003-12-03 EP claimed
US-20030186237-A1 Methods and compositions of amplifying RNA BAYLOR COLLEGE OF MEDICINE 2003-10-02 US claimed
WO-2002065093-A2 METHODS AND COMPOSITIONS OF AMPLIFYING RNA BAYLOR COLLEGE OF MEDICINE (US) 2002-08-22 WO claimed
US-20260043720-A1 STABILIZED TWO-PART HEMATOXYLIN SOLUTION UTILIZING pH ADJUSTMENT VENTANA MED SYST INC (US) 2026-02-12 US disclosed
US-12496344-B2 Biophotonic materials and uses thereof FLE INT S R L (IT) 2025-12-16 US disclosed
US-12474240-B2 Stabilized two-part hematoxylin solution utilizing pH adjustment VENTANA MEDICAL SYSTEMS, INC. (US) 2025-11-18 US disclosed
CN-118078787-A Pharmaceutical application of alizarin in preventing and treating aging and neurodegenerative diseases 中国医学科学院药物研究所 2024-05-28 CN disclosed
US-11975221-B2 Anti-microbial multilayer fabric media and method for making same Shuai Danmeng (US) 2024-05-07 US disclosed
US-11953493-B2 Biophotonic methods for increasing in situ energy production and energy emission in biological cells and tissues FLE INTERNATIONAL S.R.L. (IT) 2024-04-09 US disclosed
WO-2007102146-A2 METHODS AND COMPOSITIONS FOR IDENTIFYING A CELL PHENOTYPE ZETIQ TECHNOLOGIES LTD. (IL) 2007-09-13 WO disclosed
WO-2007084429-A2 BIOLOGICAL SAMPLE PROCESSING COMPOSITION AND METHOD VENTANA MEDICAL SYSTEMS, INC. (US) 2007-07-26 WO disclosed
US-20070172911-A1 Biological sample processing composition and method VENTANA MEDICAL SYSTEMS, INC. 2007-07-26 US disclosed
EP-1366196-A4 METHODS AND COMPOSITIONS OF AMPLIFYING RNA BAYLOR COLLEGE MEDICINE (US) 2004-07-07 EP disclosed
EP-1366196-A2 METHODS AND COMPOSITIONS OF AMPLIFYING RNA BAYLOR COLLEGE OF MEDICINE (US) 2003-12-03 EP disclosed
US-20030186237-A1 Methods and compositions of amplifying RNA BAYLOR COLLEGE OF MEDICINE 2003-10-02 US disclosed
WO-2002065093-A2 METHODS AND COMPOSITIONS OF AMPLIFYING RNA BAYLOR COLLEGE OF MEDICINE (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170315031-A1 TISSUE AND CELL STAIN FORMULA WITH A NOVEL MOLECULE OBTAINED FROM PAPAVER RHOEAS MYADM, PRSS8, MKI67 MEN1 3419/4885KMT2A 910/4885MAPT 1972/4885
US-20260043720-A1 STABILIZED TWO-PART HEMATOXYLIN SOLUTION UTILIZING pH ADJUSTMENT SMCHD1, KIT, CD68 MEN1 53/4885KMT2A 897/4885MAPT 1864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.